SCHEMBL4498835

SCHEMBL4498835

CCOC(C)(C)C(=O)c1cccs1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.48
NPC1 O15118 4/20 0.48
RAB9A P51151 4/20 0.48
HPGD P15428 4/20 0.48
ALDH1A1 P00352 6/20 0.46
KMT2A Q03164 3/20 0.46
LMNA P02545 2/20 0.46
MEN1 O00255 2/20 0.46
POLB P06746 1/20 0.46
CES2 O00748 1/20 0.46
CES1 P23141 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
DAO P14920 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
GSK3B P49841 1/20 0.43
KDM4E B2RXH2 2/20 0.43
GAA P10253 1/20 0.43
HTT P42858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3196141 0.77 TSHR (0.51) TSHRNPC1RAB9AHPGDALDH1A1
SCHEMBL11551354 0.77 CES2 (0.46) TSHRNPC1RAB9AHPGDALDH1A1
SCHEMBL3181932 0.76 CES2 (0.58) TSHRNPC1RAB9AHPGDALDH1A1
SCHEMBL3732383 0.76 CES2 (0.58) TSHRNPC1RAB9AHPGDALDH1A1
SCHEMBL11551350 0.75 CES2 (0.44) TSHRNPC1RAB9AHPGDALDH1A1
SCHEMBL4867753 0.75 CES2 (0.52) TSHRNPC1RAB9AHPGDALDH1A1
Methoxymethane SCHEMBL28663658 0.75 KMT2A (0.45) TSHRNPC1RAB9AHPGDALDH1A1
SCHEMBL22955796 0.75 TSHR (0.49) TSHRNPC1RAB9AHPGDALDH1A1
SCHEMBL15120382 0.74 CES2 (0.56) TSHRNPC1RAB9AHPGDALDH1A1
SCHEMBL29232767 0.74 ALDH1A1 (0.46) TSHRNPC1RAB9AHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1615898-B1 2-Aminopyrimidine derivatives and their medical use NOVARTIS AG (CH) 2014-10-29 EP disclosed
US-7615562-B2 Such as 2-methyl-4-{5-[2-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidin-4-yl]-thiophen-2-yl}-butan-2-ol; tumor necrosis factor inhibitors; immunosuppressants; antiinflammatory agents NOVARTIS AG (CH) 2009-11-10 US disclosed
US-20070043048-A1 2-Aminopyrimidine derivatives and their medical use NOVARTIS AG (CH) 2007-02-22 US disclosed
EP-1615898-A1 2-AMINOPYRIMIDINE DERIVATIVES AND THEIR MEDICAL USE Novartis AG (CH) 2006-01-18 EP disclosed
WO-2004089913-A1 AMINOPYRIMIDINE DERIVATIVES AND THEIR MEDICAL USE NOVARTIS AG (CH) 2004-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043048-A1 2-Aminopyrimidine derivatives and their medical use TPMT, IKBKB, CHUK TSHR 4725/4885NPC1 4005/4885RAB9A 4057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.